S&P Affirms East Midlands Electricity Ratings Dec 95

  • ID: 1786687
  • December 1995
  • Standard & Poors
1 of 3

LONDON -- Standard & Poor's CreditWire 12/15/95 -- Standard & Poor's affirms its double-`A' long-term and its `A-1'-plus short-term rating on East Midlands Electricity PLC (EME) and maintains its negative long-term rating outlook. The rating affirmation accounts for the financial effects of the recently announced special dividend. The ratings continue to reflect the company's cash generative core business, a stable regulatory environment, and reduced involvement in noncore activities. In the fall of 1994, the company offered its shareholders a UK187 million special dividend as part of its balance sheet restructuring. On Dec. 13, 1995 EME confirmed its intention to offer its National Grid shares to shareholders, and announced a further special dividend of UK238.1 million payable at fiscal 1996 year-end....

Companies mentioned in this report are:
- Western Power Distribution (East Midlands) PLC

Action: New Rating

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

Note: Product cover images may vary from those shown
2 of 3

- Western Power Distribution (East Midlands) PLC

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown





Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.